HLHeng Lu

Heng Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heng Lu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Yiqi Zhang

    The First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, 110001, PR China

    3 shared publications
  • Ang Zheng

    Department of Breast Surgery, The First Hospital of China Medical University

    2 shared publications
  • Yinlin Li

    The First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, 110001, PR China

    2 shared publications
  • Ang Zheng

    The First Affiliated Hospital of China Medical University

    1 shared publication
  • Chunyu Wang

    Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission, and Key Laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang, People’s Republic of China

    1 shared publication
  • Feng Jin

    Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    BAP18, as a corepressor of AR together with the SIN3A/HDAC complex, promotes AR-positive triple-negative breast cancer progression

    by Yiqi Zhang, Zining Jin, Yi Wu, Xueying Tang, Chunyu Wang, Shengli Wang, Yinlin Li, Tian Zhang, Feng Jin, Heng Lu, et al.

    Triple-negative breast cancer (TNBC) is considered a highly heterogeneous disease. Androgen receptor (AR)-positive TNBC is a subtype with distinct molecular features. However, the molecular mechanism underlying the modulation of the AR signaling pathway in TNBC is still elusive. BPTF-associated protein of 18 kDa (BAP18) was significantly upregulated in AR-positive TNBC samples and was positively correlated with advanced disease stage and poor prognosis. BAP18 was shown to act as a transcriptional corepressor of AR in AR-positive TNBC cells and is involved in the promotion of AR-positive TNBC. Mechanically, BAP18 associates with AR and the SIN3A/HDAC subcomplex. BAP18 facilitates the recruitment of SIN3A/HDAC to androgen response elements (AREs) in the promoter regions of P21 and PTEN, subsequently leading to a reduced level of histone H4 acetylation on AREs. Our study revealed that BAP18, which acts as a novel AR corepressor, is involved in AR-positive TNBC progression, suggesting that BAP18 could be a potential therapeutic target for AR-positive TNBC patients.

  • Open Access

    SNORA5A regulates tumor-associated macrophage M1/M2 phenotypes via TRAF3IP3 in breast cancer

    by Yiqi Zhang, Ang Zheng, Yue Shi, Heng Lu

    Small nucleolar RNAs (snoRNAs) have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. Samples from The Cancer Genome Atlas (TCGA) were reviewed. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue samples. SNORA5A was significantly down-regulated in breast cancer, and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced a high concentration of tumor-associated macrophages M1 and a low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relationship with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.


  • Open Access

    SNORA5A regulates tumor-associated macrophage M1/M2 phenotypes via TRAF3IP3 in breast cancer

    by Yiqi Zhang, Ang Zheng, Yue Shi, Heng Lu

    SnoRNAs have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. This study reviewed samples from TCGA. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue sample. SNORA5A was significantly down-regulated in breast cancer and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced high concentration of tumor-associated macrophages M1 and low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relation with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. Hence, SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.